Detailed Review,XG-102 (brimapitide) is a dextrogyre configurated protease-resistant peptide

The term dextrogyre peptides refers to a specific class of molecules characterized by their unique structural orientation. In chemistry, "dextrogyre" (often abbreviated as D) indicates that a molecule rotates plane-polarized light to the right. This property is crucial in understanding the biological activity and stability of these peptides. The scientific community's interest in dextrogyre compounds extends across various fields, from pharmaceuticals to materials science, highlighting their versatile potential.

Dextrogyre peptides are distinguished from their levogyre (L) counterparts by the spatial arrangement of their constituent amino acids. While natural peptides are predominantly composed of L-amino acids, the incorporation of dextrogyre (D) amino acids can confer significant advantages. One such benefit is increased resistance to enzymatic degradation by proteases, which typically target L-amino acid linkages. This enhanced stability can prolong the half-life of therapeutic peptides, making them more effective in vivo. Research has shown that D-Ctl consists of the same sequence as L-Ctl but with the levogyre (L) amino acids replaced by dextrogyre (D) amino acids, leading to improved efficacy and reduced resistance development in certain applications. For instance, D-Ctl can be considered as an effective, safe and stable antifungal agent, offering a promising alternative for treating fungal infections.

A notable example of a dextrogyre peptide is XG-102, also known as brimapitide. This compound is a TAT-coupled dextrogyre peptide that acts as a selective inhibitor of c-Jun N-terminal kinase (JNK). JNK is a key signaling molecule involved in inflammatory processes. By inhibiting JNK, XG-102 has demonstrated therapeutic potential in various inflammatory conditions. Clinical studies have investigated its efficacy, including its use as a coupled dextrogyre peptide for ocular inflammation. Research has shown that XG-102 (brimapitide) is a dextrogyre configurated protease-resistant peptide that selectively inhibits c-Jun N-terminal Kinase (JNK). Furthermore, XG-102 dextrogyre is a peptide derived from the conjugation of a dextrogyre peptide with kinase inhibitory properties to TAT, a cell-penetrating peptide sequence. This conjugation enhances cellular uptake, allowing the peptide to reach its intracellular targets more effectively. In 2012, XG-102, a TAT-coupled dextrogyre peptide inhibiting the c-Jun N-terminal kinase, successfully passed a phase-I clinical trial, underscoring its early promise in therapeutic development.

The application of dextrogyre peptides extends beyond JNK inhibition. Their unique properties make them valuable in drug delivery systems. Cell-penetrating peptides (CPPs), which are short peptides (fewer than 30 amino acids), are increasingly utilized for their ability to transport therapeutic molecules across cell membranes. The incorporation of a dextrogyre peptide into these delivery systems can enhance their stability and efficacy. Research into peptide-based delivery of therapeutics in cancer treatment highlights the role of targeting, cell-penetrating, and fusogenic peptides as delivery systems. The development of modularized viromimetic polymer nanoparticle vaccines also points towards innovative approaches in drug and vaccine delivery, where peptide components can play a crucial role.

The synthesis and characterization of dextrogyre peptides involve advanced techniques. For instance, the preparation of pure eutomers, such as dextrogyre R-enantiomers, can be achieved through chiral preparative HPLC. This precise control over stereochemistry is essential for ensuring the desired biological activity and minimizing off-target effects. Solid-phase peptide synthesis also allows for the incorporation of modified amino acids, including dextrogyre (D) amino acids, to create peptides with tailored properties.

In summary, dextrogyre peptides represent a significant area of scientific inquiry due to their enhanced stability and unique biological activities. From their role as therapeutic agents, such as the JNK inhibitor XG-102, to their incorporation into advanced drug delivery systems, these molecules offer exciting possibilities for future medical advancements. The ability to synthesize and utilize peptides with specific dextrogyre configurations opens new avenues for combating diseases and improving patient outcomes. The ongoing exploration into what are peptides and their diverse applications, including those with dextrogyre properties, continues to expand our understanding of these fundamental biological building blocks.